

Abstract

Novel polymorphic Crystal forms of 5-(2-{{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the β 2 adrenergic receptor

The present invention is directed to novel polymorphic crystal forms of a 5-(2-{{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1*H*)-one, heminapadisylate. The invention is also directed to pharmaceutical compositions comprising said polymorphic crystal forms, methods of using them to treat respiratory diseases associated with β 2 adrenergic receptor activity and a process for preparing such polymorphic crystal forms.

Figure for publication: None